Review
. 2015 Nov; 3(18):267.
doi: 10.3978/j.issn.2305-5839.2015.10.27.

Immune checkpoint inhibitors: therapeutic advances in melanoma

Ivan Márquez-Rodas 1 Pablo Cerezuela 1 Ainara Soria 1 Alfonso Berrocal 1 Aldo Riso 1 María González-Cao 1 Salvador Martín-Algarra 1 
Affiliations
  • PMID: 26605313
  •     76 References
  •     39 citations

Abstract

In recent years, new strategies for treating melanoma have been introduced, improving the outlook for this challenging disease. One of the most important advances has been the development of immunotherapy. The better understanding of the role of the immunological system in tumor control has paved the way for strategies to enhance the immune response against cancer cells. Monoclonal antibodies (mAbs) against the immune checkpoints cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have demonstrated high activity in melanoma and other tumors. Ipilimumab, an anti CTLA-4 antibody, was the first drug of this class that was approved. Although the response rate with ipilimumab is low (less than 20% of patients have objective responses), 20% of patients have long survival, with similar results in the first and second line settings. Nivolumab and pembrolizumab, both anti PD-1 inhibitors, have been approved for the treatment of melanoma, with response rates of 40% and a demonstrated survival advantage in phase III trials. This has marked a new era in the treatment of metastatic melanoma and much research is now ongoing with other drugs targeting checkpoint inhibitors. In addition, the agonist of activating molecules on T cells and their combinations are being investigated. Herein we review the clinical development of checkpoint inhibitors and their approval for treatment of metastatic melanoma.

Keywords: Checkpoint inhibitors; immunotherapy; melanoma; programmed cell death protein 1 (PD-1).

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.
Li Wang, Isabelle Le Mercier, +7 authors, Randolph J Noelle.
Proc Natl Acad Sci U S A, 2014 Oct 01; 111(41). PMID: 25267631    Free PMC article.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Luis H Camacho, Scott Antonia, +8 authors, Antoni Ribas.
J Clin Oncol, 2009 Jan 14; 27(7). PMID: 19139427
Phase I/II study of ipilimumab for patients with metastatic melanoma.
Jeffrey S Weber, Steven O'Day, +5 authors, Evan Hersh.
J Clin Oncol, 2008 Nov 20; 26(36). PMID: 19018089
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Jedd D Wolchok, Bart Neyns, +14 authors, Celeste Lebbé.
Lancet Oncol, 2009 Dec 17; 11(2). PMID: 20004617
Highly Cited.
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Caglar Cekic, Yuan-Ji Day, Duygu Sag, Joel Linden.
Cancer Res, 2014 Nov 08; 74(24). PMID: 25377469    Free PMC article.
Highly Cited.
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Miguel F Sanmamed, Inmaculada Rodriguez, +14 authors, Ignacio Melero.
Cancer Res, 2015 Jun 27; 75(17). PMID: 26113085
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Alfonso Berrocal, Ana Arance, +8 authors, Spanish Melanoma Group.
Melanoma Res, 2014 Jul 22; 24(6). PMID: 25046550    Free PMC article.
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Robert H Vonderheide, Keith T Flaherty, +12 authors, Scott J Antonia.
J Clin Oncol, 2007 Mar 01; 25(7). PMID: 17327609
Highly Cited.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, +17 authors, Suzanne L Topalian.
J Clin Oncol, 2010 Jun 03; 28(19). PMID: 20516446    Free PMC article.
Highly Cited.
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Julien Fourcade, Zhaojun Sun, +14 authors, Hassane M Zarour.
Cancer Res, 2013 Dec 18; 74(4). PMID: 24343228    Free PMC article.
Highly Cited.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Sven de Vos, Andres Forero-Torres, +10 authors, Ranjana Advani.
J Hematol Oncol, 2014 Jun 13; 7. PMID: 24919462    Free PMC article.
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Zeynep Eroglu, Dae Won Kim, +9 authors, Antoni Ribas.
Eur J Cancer, 2015 Sep 15; 51(17). PMID: 26364516    Free PMC article.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Caroline Robert, Antoni Ribas, +22 authors, Adil Daud.
Lancet, 2014 Jul 19; 384(9948). PMID: 25034862
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Evan M Hersh, Steven J O'Day, +7 authors, Jeffrey S Weber.
Invest New Drugs, 2010 Jan 19; 29(3). PMID: 20082117
Highly Cited.
The ipilimumab lesson in melanoma: achieving long-term survival.
Julie Delyon, Michele Maio, Celeste Lebbé.
Semin Oncol, 2015 May 13; 42(3). PMID: 25965357
Review.
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
J Louise Lines, Lorenzo F Sempere, +2 authors, Randolph Noelle.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894088    Free PMC article.
Highly Cited.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth.
Melanie Mediavilla-Varela, Kimberly Luddy, +4 authors, Scott J Antonia.
Cancer Biol Ther, 2013 Aug 07; 14(9). PMID: 23917542    Free PMC article.
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
A K Nowak, A M Cook, +10 authors, R A Lake.
Ann Oncol, 2015 Sep 20; 26(12). PMID: 26386124
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Andrea Wang-Gillam, Stacey Plambeck-Suess, +9 authors, Williams G Hawkins.
Invest New Drugs, 2012 Aug 07; 31(3). PMID: 22864469    Free PMC article.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Idit Sagiv-Barfi, Holbrook E K Kohrt, +3 authors, Ronald Levy.
Proc Natl Acad Sci U S A, 2015 Mar 03; 112(9). PMID: 25730880    Free PMC article.
Highly Cited.
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
John C Morris, Antoinette R Tan, +6 authors, Donald P Lawrence.
PLoS One, 2014 Mar 13; 9(3). PMID: 24618589    Free PMC article.
Highly Cited.
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Giovanna Bossi, Sandrine Buisson, +2 authors, Namir J Hassan.
Cancer Immunol Immunother, 2014 Feb 18; 63(5). PMID: 24531387
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.
Guido Kroemer, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 04; 4(7). PMID: 26140249    Free PMC article.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
An immune-active tumor microenvironment favors clinical response to ipilimumab.
Rui-Ru Ji, Scott D Chasalow, +9 authors, Vafa Shahabi.
Cancer Immunol Immunother, 2011 Dec 08; 61(7). PMID: 22146893
Highly Cited.
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
Carsten Linnemann, Marit M van Buuren, +13 authors, Ton N M Schumacher.
Nat Med, 2014 Dec 23; 21(1). PMID: 25531942
Highly Cited.
Nivolumab: a review of its use in patients with malignant melanoma.
Emma D Deeks.
Drugs, 2014 Jul 16; 74(11). PMID: 25022950
Review.
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
Jens Rüter, Scott J Antonia, +2 authors, Robert H Vonderheide.
Cancer Biol Ther, 2010 Sep 22; 10(10). PMID: 20855968    Free PMC article.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Nivolumab + ipilimumab ups melanoma response.
Cancer Discov, 2015 Apr 23; 5(6). PMID: 25898833
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, +25 authors, James Larkin.
Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410
Highly Cited.
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Jeffrey S Weber, Ragini Reiney Kudchadkar, +11 authors, Y Ann Chen.
J Clin Oncol, 2013 Oct 23; 31(34). PMID: 24145345    Free PMC article.
Highly Cited.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, +33 authors, Adil Daud.
Lancet Oncol, 2015 Jun 28; 16(8). PMID: 26115796    Free PMC article.
Highly Cited.
Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Omid Hamid.
Clin Adv Hematol Oncol, 2015 Feb 13; 12(11). PMID: 25674719
Review.
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Gregory L Beatty, Drew A Torigian, +8 authors, Peter J O'Dwyer.
Clin Cancer Res, 2013 Aug 29; 19(22). PMID: 23983255    Free PMC article.
Highly Cited.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
David McDermott, Celeste Lebbé, +5 authors, Charles M Balch.
Cancer Treat Rev, 2014 Jul 26; 40(9). PMID: 25060490
Highly Cited. Review.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, +19 authors, Alessandro Testori.
Lancet Oncol, 2015 Apr 05; 16(5). PMID: 25840693
Highly Cited.
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice.
Taku Okazaki, Il-mi Okazaki, +9 authors, Tasuku Honjo.
J Exp Med, 2011 Feb 09; 208(2). PMID: 21300912    Free PMC article.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Jeffrey Weber, John A Thompson, +9 authors, Steven J O'Day.
Clin Cancer Res, 2009 Aug 13; 15(17). PMID: 19671877
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Matias E Valsecchi.
N Engl J Med, 2015 Sep 24; 373(13). PMID: 26398077
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, F Stephen Hodi, Jedd D Wolchok.
N Engl J Med, 2015 Sep 24; 373(13). PMID: 26398076
Highly Cited.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, +7 authors, Jedd D Wolchok.
Cancer, 2010 Feb 10; 116(7). PMID: 20143434    Free PMC article.
Highly Cited.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Jordi Rodón, Michael Carducci, +15 authors, Jose Baselga.
Invest New Drugs, 2014 Dec 23; 33(2). PMID: 25529192    Free PMC article.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Prospects for TIM3-Targeted Antitumor Immunotherapy.
Shin Foong Ngiow, Michele W L Teng, Mark J Smyth.
Cancer Res, 2011 Oct 20; 71(21). PMID: 22009533
Review.
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Guifang Cai, Anukanth Anumanthan, +3 authors, Gordon J Freeman.
Nat Immunol, 2008 Jan 15; 9(2). PMID: 18193050
Highly Cited.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells.
Dongchun Liang, Aijun Zuo, +3 authors, Deming Sun.
PLoS One, 2014 Oct 01; 9(9). PMID: 25268760    Free PMC article.
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Elnaz Faghfuri, Mohammad Ali Faramarzi, Shekoufeh Nikfar, Mohammad Abdollahi.
Expert Rev Anticancer Ther, 2015 Aug 28; 15(9). PMID: 26313415
Review.
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Jason A Dubovsky, Kyle A Beckwith, +26 authors, John C Byrd.
Blood, 2013 Jul 28; 122(15). PMID: 23886836    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Therapeutic use of anti-CTLA-4 antibodies.
Christian U Blank, Alexander Enk.
Int Immunol, 2014 Jul 20; 27(1). PMID: 25038057
Review.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
Robert H Vonderheide, Jennifer M Burg, +5 authors, Omid Hamid.
Oncoimmunology, 2013 Mar 14; 2(1). PMID: 23483678    Free PMC article.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Review.
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Ziying Lin, Yutong Xu, +4 authors, Wenhua Liang.
Oncotarget, 2016 Mar 02; 7(12). PMID: 26930715    Free PMC article.
Immune based therapy for melanoma.
Robert Ancuceanu, Monica Neagu.
Indian J Med Res, 2016 Apr 29; 143(2). PMID: 27121512    Free PMC article.
Review.
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
Miriam Potrony, Esther Carreras, +12 authors, Francisco Lozano.
Int J Cancer, 2016 May 14; 139(6). PMID: 27169428    Free PMC article.
Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases.
Nora Rippaus, David Taggart, +4 authors, Mihaela Lorger.
Oncotarget, 2016 May 21; 7(27). PMID: 27203741    Free PMC article.
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Xue Li, Minghuan Li, +4 authors, Jinming Yu.
Target Oncol, 2016 Jul 17; 11(6). PMID: 27422273
Systematic Review.
Toxicity management of immunotherapy for patients with metastatic melanoma.
Helena Linardou, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563659    Free PMC article.
Review.
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer.
Cell Commun Signal, 2017 Jan 20; 15(1). PMID: 28100240    Free PMC article.
Review.
Sustained epidermal powder drug delivery via skin microchannels.
Yan Cao, Prateek Kakar, +2 authors, Xinyuan Chen.
J Control Release, 2017 Jan 31; 249. PMID: 28132934    Free PMC article.
Uveal melanoma: epidemiology, etiology, and treatment of primary disease.
Benjamin A Krantz, Nikita Dave, +2 authors, Richard D Carvajal.
Clin Ophthalmol, 2017 Feb 17; 11. PMID: 28203054    Free PMC article.
Review.
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.
Sunil Thomas, Jacques Izard, +12 authors, George C Prendergast.
Cancer Res, 2017 Mar 16; 77(8). PMID: 28292977    Free PMC article.
Highly Cited. Review.
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
Nalini Marino, Sam Illingworth, +6 authors, Alice C N Brown.
PLoS One, 2017 May 26; 12(5). PMID: 28542292    Free PMC article.
Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma.
Tara Miran, Andreas T J Vogg, +5 authors, Agnieszka Morgenroth.
Cancer Med, 2017 Jun 14; 6(7). PMID: 28608446    Free PMC article.
CEACAM1 as a multi-purpose target for cancer immunotherapy.
Matthew Dankner, Scott D Gray-Owen, +2 authors, Nicole Beauchemin.
Oncoimmunology, 2017 Aug 16; 6(7). PMID: 28811966    Free PMC article.
Review.
A cellular platform for the evaluation of immune checkpoint molecules.
Sabrina Jutz, Annika Hennig, +7 authors, Peter Steinberger.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029399    Free PMC article.
Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.
Anthony Cutts, Oliver Venn, +7 authors, Anna Schuh.
NPJ Genom Med, 2017 Oct 28; 2. PMID: 29075515    Free PMC article.
Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.
Christian Ostheimer, Sophie Gunther, +2 authors, Gabriele Multhoff.
Front Immunol, 2017 Nov 03; 8. PMID: 29093708    Free PMC article.
Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.
Satwinder Mudan, Jayant Kumar, +5 authors, Nagy Habib.
Medicine (Baltimore), 2017 Dec 17; 96(49). PMID: 29245341    Free PMC article.
The role for chemotherapy in the modern management of melanoma.
Avinash Gupta, Fabio Gomes, Paul Lorigan.
Melanoma Manag, 2017 May 01; 4(2). PMID: 30190915    Free PMC article.
Review.
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Silvia Cantara, Eugenio Bertelli, +5 authors, Paolo Toti.
Endocrine, 2019 Feb 15; 64(1). PMID: 30762153
The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Anja Wessely, Theresa Steeb, +5 authors, Markus Vincent Heppt.
Int J Mol Sci, 2020 Feb 06; 21(3). PMID: 32013269    Free PMC article.
Review.
PD-1 IC Inhibition Synergistically Improves Influenza A Virus-Mediated Oncolysis of Metastatic Pulmonary Melanoma.
Siarhei Sitnik, Dörthe Masemann, +2 authors, Stephan Ludwig.
Mol Ther Oncolytics, 2020 Apr 30; 17. PMID: 32346609    Free PMC article.
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Young-Dae Kim, Sang-Min Park, +5 authors, Joong Myung Cho.
J Cancer, 2020 May 06; 11(14). PMID: 32368288    Free PMC article.
NK Cell-Based Immunotherapies in Cancer.
Min Hwa Shin, Junghee Kim, +3 authors, Kyung-Mi Lee.
Immune Netw, 2020 May 13; 20(2). PMID: 32395366    Free PMC article.
Review.
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.
Carlo Gabriele Tocchetti, Christian Cadeddu, +12 authors, Giuseppe Mercuro.
Antioxid Redox Signal, 2017 Apr 12; 30(18). PMID: 28398124    Free PMC article.
Review.
Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential.
Stina George Fernandes, Rebecca Dsouza, +5 authors, Ekta Khattar.
Cancers (Basel), 2020 Jul 18; 12(7). PMID: 32674474    Free PMC article.
Review.
Pembrolizumab-induced bullous pemphigoid.
Christina W Sun, Shoshana K Grossman, Abhishek Aphale, Sylvia Hsu.
JAAD Case Rep, 2019 Apr 23; 5(4). PMID: 31008169    Free PMC article.
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
Katrin Goepfert, Christiane Dinsart, +2 authors, Markus Moehler.
Front Oncol, 2019 Jun 14; 9. PMID: 31192129    Free PMC article.
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Leilei Ai, Jian Chen, +4 authors, Xiaochun Yang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982171    Free PMC article.
Review.
Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
Jong Shin, Paul J Phelan, +2 authors, Peter A Bullock.
Protein Expr Purif, 2020 Sep 29; 177. PMID: 32987122    Free PMC article.
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
Min Zhang, Jingwen Yang, +3 authors, Qijun Qian.
Front Med, 2019 Jan 27; 13(1). PMID: 30680606
Review.
Telomerase-Targeted Cancer Immunotherapy.
Eishiro Mizukoshi, Shuichi Kaneko.
Int J Mol Sci, 2019 Apr 25; 20(8). PMID: 31013796    Free PMC article.
Review.
Stepping From Modeling Cancer Plasticity to the Philosophy of Cancer.
Jean Clairambault.
Front Genet, 2020 Dec 18; 11. PMID: 33329717    Free PMC article.
Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets.
Quanyin Hu, Hongjun Li, +8 authors, Zhen Gu.
Nat Biomed Eng, 2021 Apr 28; 5(9). PMID: 33903744    Free PMC article.
Infiltration of Immune Competent Cells into Primary Tumors and Their Surrounding Connective Tissues in Xenograft and Syngeneic Mouse Models.
Marlon Metzen, Michael Bruns, Wolfgang Deppert, Udo Schumacher.
Int J Mol Sci, 2021 May 01; 22(8). PMID: 33921688    Free PMC article.
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
Ha Nguyen, Komal Shah, +13 authors, Ramona Dadu.
Endocr Relat Cancer, 2021 Apr 24; 28(7). PMID: 33890870    Free PMC article.
Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
Rosalba Buquicchio, Valentina Mastrandrea, +3 authors, Raffaele Filotico.
Front Oncol, 2021 Sep 21; 11. PMID: 34540666    Free PMC article.
The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.
Silvia Gitto, Ambra Natalini, Fabrizio Antonangeli, Francesca Di Rosa.
Front Immunol, 2021 Dec 07; 12. PMID: 34867987    Free PMC article.
Review.
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Maria Luigia Carbone, Gabriele Madonna, +10 authors, Cristina Maria Failla.
Sci Rep, 2022 Apr 02; 12(1). PMID: 35361879    Free PMC article.